Physician

Amit M. Patel, M.D.

According to 2025 Medicare claims, Amit Patel, M.D. (NPI: 1346553120) practices dermatology in the Beaumont-Port Arthur, TX market, with the plurality of this provider's patient population coming from Jefferson, TX. This provider's primary affiliated billing organization is CORIUM VENTURES PLLC (NPI: 1770098261; TIN: 813683533) and primary practice location at 77642-8023.

Patel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 844 traditional Medicare patients, billed 8,639 HCPCS/CPT codes, and received $454,436 in Medicare payments. The top billing code was 17004 (Destruction of precancer skin growth, 15 or more growths). Part D data shows 3,732 prescription claims across 1,214 beneficiaries totaling $1,165,288 in drug costs, led by Tremfya (Guselkumab). Open Payments data shows 25 records totaling $6,879. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $239,630 to $454,436. Similarly, Part D prescription costs have moved sharply higher in recent years, from $72,694 to $1,165,288. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$236K$471K2015 Medicare payment: $239,630 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $41,717 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $221,862 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $405,370 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $351,858 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $369,791 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $338,163 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $471,108 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $454,436 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20158825,817$239,630
20162861,355$41,717
2017N/RN/RN/R
20186023,746$221,862
20197137,294$405,370
20207166,089$351,858
20216725,673$369,791
20226515,827$338,163
20237508,236$471,108
20248448,639$454,436

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$751K$1.5M2015 Drug cost: $72,694 (USD; Tot_Drug_Cst)2016 Drug cost: $66,050 (USD; Tot_Drug_Cst)2017 Drug cost: $208,014 (USD; Tot_Drug_Cst)2018 Drug cost: $285,122 (USD; Tot_Drug_Cst)2019 Drug cost: $337,050 (USD; Tot_Drug_Cst)2020 Drug cost: $470,697 (USD; Tot_Drug_Cst)2021 Drug cost: $757,320 (USD; Tot_Drug_Cst)2022 Drug cost: $928,984 (USD; Tot_Drug_Cst)2023 Drug cost: $1,501,507 (USD; Tot_Drug_Cst)2024 Drug cost: $1,165,288 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015224442$72,694
2016295589$66,050
20174771,391$208,014
20186402,166$285,122
20197142,302$337,050
20207422,441$470,697
20211,1833,642$757,320
20221,2203,978$928,984
20231,3834,638$1,501,507
20241,2143,732$1,165,288

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17004Destruction of precancer skin growth, 15 or more growths322589$114
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more5911,142$85
17110Destruction of skin growth, 1-14 growths351484$67
17000Destruction of precancer skin growth, 1 growth444640$32
17003Destruction of precancer skin growth, 2-14 growths3933,207$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
TremfyaGuselkumab181,008$240,474
OtezlaApremilast461,380$217,854
Cosentyx Sensoready (2 Pens)Secukinumab27756$192,012
Humira PenAdalimumab12333$156,174
OpzeluraRuxolitinib Phosphate13365$26,450

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.25$6,879E.R. Squibb & Sons, L.L.C.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Amit M. Patel, M.D.?

Tedicare shows public-source Medicare data for Amit M. Patel, M.D. (NPI 1346553120), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amit M. Patel, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amit M. Patel, M.D.?

Amit M. Patel, M.D. is linked to CORIUM VENTURES PLLC (billing NPI 1770098261) in the available physician profile data.

Does Amit M. Patel, M.D. have Open Payments data?

Amit M. Patel, M.D. has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.